Wyeth Pharmaceuticals Inc. One Blue Hill Plaza, 21st Floor Pearl River, NY 10965 Global Regulatory Affairs
Jack D. Love, Ph.D.
Assistant Vice President
Global Regulatory Affairs



February 1, 2008

STN 101106 Smallpox Vaccine, Dryvax®

Dr. Cindy Dougherty Centers for Disease Control/Drug Service, D-09 1600 Clifton Road Atlanta, GA 30333

LTC Patrick Garman
Deputy Director, Scientific Affairs
Military Vaccine Agency
Office of the Surgeon General
5113 Leesburg Pike (Suite 402)
Falls Church, VA 22041-3258

Dear Dr. Dougherty and LTC Garman:

I am writing this letter to advise you of Wyeth's intention to withdraw its Smallpox Vaccine, Dryvax® from the field. Please note that the withdrawal is not necessitated by any safety, purity or quality issues with the product, but rather is consistent with Modification to Contract number between Wyeth and the Centers for Disease Control and Prevention.

Based on prior discussions with CDC/DoD, Wyeth hereby requests that all remaining quantities of Smallpox Vaccine, Dryvax[®] (constituted as well as unconstituted) be quarantined for the purpose of destruction in accordance with CDC/DoD procedures and the above referenced contract by **February 29, 2008.** The remaining vaccine should be from the following lots:

Packaged Lot (Fill Lot) 4020077 (302301), 4020076 (313701), 4030020 (313601), 4020072 (321401), 4020074 (321301), 4020075 (317602), 4030013 (317401) and 4030014 (302501).

We also request that CDC provide Wyeth with written certification of quarantine and destruction of all product when completed.

If you have any questions, please contact Dr. Dennis Foley at (914) 319-9002.

Wyeth

Sincerely,

Jack D Love, Ph.D. Assistant Vice President Global Regulatory Affairs

cc: J. Becher, ORISE fellow D Foley, AMDG Consulting Hye-Joo Kim, CDC D. Staten, CBER